Trinity Biotech Plc

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trinity Biotech reports robust Q1 results, eyes $75M revenue milestone

Trinity Biotech's Q1 2024 performance reflects strong revenue growth, margin improvement, and cost optimization efforts. Despite challenges in compliance and operational optimization, the company is poised for growth with a clear focus on key priorities and revenue targets.

Trinity Biotech reports revenue growth and operational progress in Q2

Trinity Biotech's Q2 2024 performance showed revenue growth and operational improvements, with a focus on strategic transformation and market expansion.
While facing financial challenges and cost pressures, the company is leveraging strengths in point-of-care sales and technology advancement for future success.
Opportunities for growth and profitability exist through achieving revenue targets, optimizing operations, and driving innovation in key product lines.
Overall, Trinity Biotech's progress in Q2 2024 sets a foundation for future growth and value creation, underpinned by a clear strategic roadmap.

Trinity Biotech reports growth in Q3, eyes new technology revenue

Trinity Biotech's Q3 performance showed revenue growth and progress towards financial targets. Strategic strengths in growth focus and cost optimization position the company for future success. Challenges include lower revenues and restructuring costs, while opportunities lie in new technology revenue streams and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trinity Biotech plc (NASDAQ:TRIB ) Q1 2022 Earnings Conference Call June 30, 2022 11:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Ronan O'Caoimh - Chairman and Chief Executive Officer John Gillard - Chief Financial Officer and Director Conference Call Participants Jim Sidoti - Sidoti & Co Operator Good day, and welcome to the Trinity Biotech First Quarter Financial Results Conference Call. All participants will be in a listen-only mode.

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2022 Results - Earnings Call Transcript

DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 2022.

Trinity Biotech Announces Quarter 1 2022 Financial Results

Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN Conference Call Scheduled for June 30, 2022 at 11:00 am EASTERN

Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results

DUBLIN, Ireland, May 20, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test throughout the European Union as well as other countries that recognise the CE Mark designation.

Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test

DUBLIN, Ireland, May 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced strategic investment with the MiCo Group.

Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea

Trinity Biotech plc (NASDAQ: TRIB) announced a $45 million investment and partnership with MiCo Ltd, a KOSDAQ-listed and Korea-based company. MiCo is engaged in the biomedical business through its affiliate MiCo BioMed and provides cutting-edge technology-driven solutions in.

Trinity Biotech Stock Surges After $45M Capital Infusion From Korea-Based Firm

DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021.

Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results

DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading global diagnostic company (“Trinity Biotech” or the “Company”), today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed, in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors.

Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea

Dublin-based Trinity Biotech Plc shares TRIB, -4.24% jumped 6% premarket Monday, after the company said it has received approval from the World Health Organization for its HIV screening product, TrinScreen. The company's Uni-Gold HIV product has served as the main confirmatory test for the detection of HIV in Africa for many years.

Trinity Biotech shares jump 6% premarket after WHO approves is rapid test for HIV

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO).

Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV

DUBLIN, Ireland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its recently announced refinancing.

Trinity Biotech Announces The Successful Closing of its Debt Refinancing

DUBLIN, Ireland, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Extraordinary General Meeting (EGM).

Trinity Biotech Announces That Its Shareholders Have Approved All of the Four Resolutions That Were the Subject of the EGM Held on January 25, 2022

Trinity Biotech plc (NASDAQ: TRIB) has entered into an $81.25 million loan facility to refinance the existing $99.9 million of exchangeable senior notes. The Company entered into an $81.25 million senior secured term loan credit facility with Perceptive Advisors.

Trinity Biotech Enters Into $81M Loan Facility To Refinance Existing Debt

DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Company's subsidiary, Trinity Biotech Investment Limited (the “Notes”), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.

Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company's Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q2 2021 Results - Earnings Call Transcript

The stock price of Trinity Biotech plc (NASDAQ: TRIB) increased today. This is why it happened.

TRIB Stock: Why It Increased Today

DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021.

Trinity Biotech Announces Results for Q2, 2021

Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN Conference Call Scheduled for September 9, 2021 at 11:00 am EASTERN

Trinity Biotech plc to Announce Second Quarter Fiscal Year 2021 Financial Results

DUBLIN, Ireland, July 16, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.

Trinity Biotech Provides A Business Development Update For Q2 2021

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q1 2021 Results - Earnings Call Transcript

DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021.

Trinity Biotech Announces Results for Q1, 2021

Conference Call Scheduled for May 25, 2021 at 11:00 am EASTERN Conference Call Scheduled for May 25, 2021 at 11:00 am EASTERN

Trinity Biotech plc to Announce First Quarter Fiscal Year 2021 Financial Results

Allied Healthcare Products

Allena Pharmaceuticals

China Xiangtai Food Co Ltd

Reliance Global Group

Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?

Top Penny Stocks For Your May Watchlist? Check These 5 Out

Trinity Biotech plc (TRIB) CEO Ronan O'Caoimh on Q4 2020 Results - Earnings Call Transcript

DUBLIN, Ireland, March 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2020 and fiscal year 2020.

News for Trinity Biotech Plc Stock (TRIB)